<DOC>
	<DOCNO>NCT02842138</DOCNO>
	<brief_summary>This single arm , open-label , one center , dose escalation clinical study determine safety efficacy infusion autologous T cell express CD19-redirected Chimeric Antigen Receptor ( CD19 CAR T ) adult patient relapse refractory CD19 positive B-cell lymphoma .</brief_summary>
	<brief_title>Autologous CD19 CAR T Cells Relapsed Refractory B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . CD19+ B cell lymphoma , verify IHC flow cytometry . 2. prior history least two standard care medication . 3. ineligible allogeneic transplantation relapse transplantation . 4. patient 18 year old . 5. life expectancy &gt; 3months . 6 . ECOG ≤ 2 . 7. satisfactory major organ function : adequate heart function LVEF≥50 % ; pulse oximetry ≥ 90 % ; cockcroftgault creatinine clearance≥40 ml/min ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3ULN ; Bilirubin ≤2.0 mg/dl . 8 . Blood : Hgb ≥ 80 g/L , ANC ≥ 1×10^9/L , PLT ≥ 50×10^9/L . 9. woman reproductive potential must negative pregnancy test . Male female reproductive potential must agree use birth control study one year post study . 10. measurable tumor . 1. use immunosuppressive drug systemic steroid within one week enrollment . 2. active infection . 3 . HIV positive . 4. active hepatitis B virus infection hepatitis C virus infection . 5. breastfeed pregnant woman . 6. patient refuse practice birth control study one year post study . 7. patient prior history malignance exclude study , patient cure skin basal cell carcinoma cervical cancer , tumor remove surgical resection without therapy 5 year progressionfree survival , include study . 8. currently enrol study . 9. patient , opinion investigator , may eligible able comply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>